Sonidegib is a product used to treat a certain type of skin cancer (basal cell carcinoma). In July 2015, the US FDA (Food and Drug Administration) approved sonidegib (Odomzo®; Novartis, New Jersey, USA) for the treatment of adult patients with basal cell carcinoma. in situ progression (BCC). Read more to understand more about the uses, indications and precautions when using Sonidegib.